Collectively, these results demonstrate that cysteine-engineered antibody–dye conjugates targeting EGFR, Nectin-4, and TROP-2 retain their antigen specificity and induce highly selective, light-dependent cytotoxicity in BC cells. This evidence concerns the gene EGFR and breast cancer.